Journal of Nanomaterials / 2015 / Article / Tab 1

Review Article

Recent Advances in FePt Nanoparticles for Biomedicine

Table 1

Cytotoxicity studies on FePt nanoparticles.

MaterialFe precursorSurface coatingNP concentrationCell lineTest (h)ToxicityReference

FePt-SiO2-ANa2Fe(CO)4SiO2 shell200 μg/mL
([Fe]: ~2 μg/mL)
A375M, MCF7, U2OSMTS168: no loss [42]

FePt-ANa2Fe(CO)4Cysteamine30 μg/mL
([Fe]: ~5.3 μg/mL)
A375M, MCF7, U2OS MTS168: no loss [42]
60 μg/mL
([Fe]: ~10.5 μg/mL)
72: ~10% loss

FePtFe(CO)5Cysteamine; conjugated with anti-Her2 antibody[Fe]: 0.01–100 mMVeroMTT24: >90% (below 10 mM); 
: 75% (at 100 mM)
[21]

PEGylated FePt@Fe2O3Fe(CO)5Fe2O3 shell, PEG, FA160 μg/mLKB, HeLa, MTT  24No significant cytotoxicity [47]
HL 7702 LDHNo obvious cell membrane damage

FePtFe(CO)5Folate-conjugated5~100 μg/mLEMT-6MTT24, 48No adverse toxicity effects[44]

SiW11O39-FePtC10H14FeO4Silicone-tungsten-oxide0.015 mg/mL Rat cortical brain astrocytesTrypan blue exclusion, flow-cytometric annexin/PI apoptosis 24: 80%,  
: 5.4% 
[49]
0.25 mg/mL: 23%, 
: 28.5%

SiWxOy-FePt C9H9FeO6Hydrophilic
SiWxOy first shell
0.015 mg/mLRat cortical brain astrocytesTrypan blue exclusion, flow-cytometric annexin/PI apoptosis 24: 81%, 
: 7.6% 
[49]
0.25 mg/mL: 35.7%, 
: 26.2%

FePt-CysFeCl2⋅H2OL-Cysteine100 μg/mL ECV304, HEK293, L929MTT72: ~110.2% (ECV304); 
: no obvious decrease (HEK293 or L929)
[50]

PEGylated FePt–Fe3O4 composite nanoassemblies (CNAs)FeCl2⋅4H2O,Fe3O4, PEGylated 2.0 mg mL−1L929, HeLaSRB assay24Low cytotoxicity to L929;  
over 20% of HeLa cells died
[51]

NP is nanoparticle; is the incubation time; [Fe] is the Fe concentration; is the cell damage; is the cell viability; is the cell apoptosis.